<DOC>
	<DOC>NCT00950599</DOC>
	<brief_summary>To evaluate the positive efficacy trend among doses of saxagliptin (BMS-477118) in subjects with Type 2 diabetes mellitus by assessing the change from baseline in HbA1c following 12 weeks of double-blind treatment.</brief_summary>
	<brief_title>Study of Multiple Doses of Saxagliptin (BMS-477118)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<criteria>Type 2 diabetes who are drugnaive Screening HbA1c ≥ 6.8% and ≤ 9.7% Screening fasting or random Cpeptide &gt; 0.5 ng/mL &lt; 35 years old must be negative for antiGAD antibodies Body Mass Index &lt; 35 kg/m2 Symptoms of poorly controlled diabetes History of diabetic ketoacidosis, hyperosmolar nonketotic coma, or insulin therapy within one year of screening Receipt of oral antihyperglycemic medications for more than six months in total since diagnosis Significant cardiovascular history</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>